Skip to main content

Table 3 Right ventricular regional (segmental) strain values stratified by diagnostic groupd

From: Feature tracking CMR reveals abnormal strain in preclinical arrhythmogenic right ventricular dysplasia/ cardiomyopathy: a multisoftware feasibility and clinical implementation study

  Overt ARVD/C (N = 39) Preclinical ARVD/C (N = 40) Controls
(N = 31)
P-Valuec
Subtricuspid Region
 MEDIS −-28.4 ± 14.8a −31.6 ± 10.4a −38.1 ± 8.1 0.007
 TOMTEC −24.7 ± 18.3a −32.4 ± 12.6 −34.3 ± 11.4 0.045
 MTT −24.4 ± 10.8ab −33.4 ± 10.9 −36.9 ± 10.5 <0.001
 CIRCLE −23.0 ± 8.4a −26.2 ± 6.3 −27.0 ± 5.0 0.067
Anterior Wall Region
 MEDIS −20.6 ± 10.5ab −28.6 ± 10.3 −29.0 ± 11.1 0.001
 TOMTEC −17.5 ± 11.9 −19.7 ± 11.1 −22.6 ± 12.5 0.248
 MTT −17.7 ± 6.4 ab −23.0 ± 6.1 −22.8 ± 6.3 0.001
 CIRCLE −22.8 ± 6.2 −24.2 ± 5.0 −25.3 ± 3.4 0.168
Apical Region
 MEDIS −22.8 ± 10.0b −27.8 ± 8.7 −25.1 ± 9.6 0.072
 TOMTEC −12.7 ± 10.7 −14.7 ± 10.4 −13.1 ± 8.6 0.674
 MTT −18.6 ± 8.8ab −23.3 ± 7.8 −25.5 ± 9.6 0.019
 CIRCLE −18.3 ± 5.4 −19.9 ± 5.1 −19.5 ± 5.6 0.521
  1. a Statistical significant difference compared to control subjects; b Statistical significant difference compared to preclinical subjects; c Trend between overt ARVD/C patients, preclinical ARVD/C and control subjects (OneWay ANOVA). Abbreviations: ARVD/C = Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy; MTT = Multimodality Tissue Tracking; N = number of subjects
  2. dSegments included based on adequate tracking quality: 365/438, 429/468, and 328/360 segments in overt ARVD/C, preclinical ARVD/C and control subjects respectively